Intravenous immunoglobulins control scleromyxoedema.
BACKGROUND
Scleromyxoedema is a variant of papular mucinosis affecting the skin and internal organs. The different therapeutic approaches proposed for scleromyxoedema are still unsatisfactory. Intravenous immunoglobulin (IVIg) has been successfully employed in the treatment of connective tissue diseases and vasculitides.


METHODS
The successful treatment of three cases of scleromyxoedema with IVIg is reported here.


CONCLUSIONS
The relatively low risk of the drug and the high effectiveness seen in three patients suggest that IVIg is a new treatment potentially useful in scleromyxoedema.
Righi
A
A
Department of Medicine, Division of Rheumatology, University of Florence, Italy.
Schiavon
F
F
Jablonska
S
S
Doria
A
A
Blasczyk
M
M
Rondinone
R
R
Todesco
S
S
Matucci Cerinic
M
M
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008297:Male; D009230:Myxedema / Q000175:diagnosis / Q000628:therapy*; D016879:Salvage Therapy / Q000379:methods; D016896:Treatment Outcome
D016756:Immunoglobulins, Intravenous